Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients

Indian Journal of Psychiatry

Volumn 51, Issue 3, 2009, Pages 202-205

  Sarkar, Pradyot ^a   Natarajan, Chandrashekhar ^a   Gode, Neeta ^b  

^a Dept of Plastic Surgery   (India)

^b MILITARY HOSPITAL   (India)

Author keywords

Haloperidol; Manic episode; Neuroleptic malignant syndrome; Neuroleptics

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CHLORPROMAZINE; CLONAZEPAM; DIAZEPAM; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PROMETHAZINE; TRIHEXYPHENIDYL; VALPROIC ACID; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL EXAMINATION; HOSPITAL PATIENT; HUMAN; INDIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MANIA; NEUROLEPTIC MALIGNANT SYNDROME; PREVALENCE; PSYCHOSIS;

EID: 77953393093     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.55089     Document Type: Article

References (18)

1. Janicak PG, Beedle D. Medication-induced movement disorders. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock s Comprehensive Text Book of Psychiatry, 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 2714-2715
2. Addomizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: Review and analyses of 115 cases. Biol Psychiatry 1987;22:1004-1020
3. Marangell LB, Silver JM, Goff DC, Yudotsky SC. Psychopharmacology and electroconvulsive therapy. In: Hales RE, Yudofsky SG, editors. Text Book of Clinical Psychiatry, 4th ed. Washington DC: American Psychiatric Publishing, Inc; 2003. p. 1091-1092
4. Hsin-tung PIE, Simpson GM. Medication-induced movement disorders. In: Sadock BJ, Sadock VA, editors. Kaplan and Sadock s Comprehensive Text Book of Psychiatry, 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2000. p. 2266-2267
5. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry 1986;143:1587-1589
6. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:219-235
7. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic criteria for research: Geneva: 1992.
8. American Medical Association. AMA Drug Evaluations 1992: Chicago: 1992.
9. Harsch HH. Neuroleptic malignant syndrome: Physiological and laboratory findings in a series of nine cases. J Clin Psychiatry 1987;48:328-333
10. Naganuma H, Fujii I. Incidence and risk factors in neuroleptic malignant syndrome. Acta Psychiatr Scand 1994;90:424-426
11. Sachdev P, Mason C, Hadzi-Pavlovic D. Case control study of neuroleptic malignant syndrome. Am J Psychiatry 1997;154:1156-1158
12. Stoudemire A, Luther JS. Neuroleptic malignant syndrome and neuroleptic induced catatonia: Differential diagnosis and treatment. Int J Psychiatry Med 1984;14:57-63.
13. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q 2001;72:325-336
14. Fricchione GL. Neuroleptic catatonia and its relationship to psychogenic catatonia. Biol Psychiatry 1985;20:304-313
15. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989;146:717-725 (Pubitemid 19149581)
16. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989;46:914-918
17. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169-180
18. Adityanjee PA, Singh S, Singh G, Ong S. Spectrum concept of neuroleptic malignant syndrome. Br J Psychiatry 1988;153:107-111